If You Invested in Alps Group Inc. (ALPS)
Looking for the current price? See the ALPS quote & overviewWhat $1,000 or $10,000 in ALPS Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Oct 19, 2021 |
|---|---|---|---|---|
| $1,000 | $125 -88% | — | — | $99 -90% |
| $10,000 | $1,250 -88% | — | — | $990 -90% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-08-14. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for ALPS$1,000 Investment Over Time
ALPS vs S&P 500Year-by-Year Returns
ALPS annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021 | $3.23 | $3.42 | +5.7% | +5.7% |
| 2022 | $3.42 | $5.01 | +46.6% | +55.0% |
| 2023 | $5.09 | $0.0161 | -99.7% | -99.5% |
| 2025 | $2.56 | $0.8694 | -66.0% | -73.1% |
| 2026 | $0.9110 | $0.32 | -64.9% | -90.1% |
About Alps Group Inc.
Mining, Quarrying, and Oil and Gas Extraction · NASDAQ
ALPS Group Inc (NASDAQ: ALPS) is described in recent company communications as a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine. The company is the parent of Alps Life Sciences Inc., which is characterized as an integrated biotechnology platform that brings together research and development, medical services, and wellness solutions of advanced therapies within a unified ecosystem. According to its stated mission, ALPS Group aims to promote a fair healthcare ecosystem by improving accessibility and affordability of advanced healthcare.
Following the completion of a business combination with Globalink Investment Inc., a special purpose acquisition company, ALPS Group Inc became the surviving publicly traded entity and its ordinary shares trade on the Nasdaq Stock Market under the ticker symbol ALPS. After this transaction, the company’s headquarters is described as being located in Kuala Lumpur, Malaysia. The business combination structure involved a redomestication merger and an acquisition merger, resulting in Alps Life Sciences Inc becoming a wholly owned subsidiary of ALPS Group Inc.
Business focus and platform
Based on the company’s own description, ALPS Group Inc focuses on building an integrated biotechnology and healthcare platform. Its activities are presented as integrating:
- Biotechnology research and development
- Medical services related to advanced therapies
- Wellness solutions aligned with predictive, preventive, and precision medicine
The company’s stated objective is to improve healthcare outcomes globally by advancing predictive, preventive, and precision medicine and by working toward accessibility and affordability of such care. The platform is positioned as unifying scientific research, clinical applications, and wellness-oriented offerings under one ecosystem.
Corporate structure and background
ALPS Group Inc is identified as the parent company of Alps Life Sciences Inc. In connection with its listing on Nasdaq, ALPS Group Inc completed a business combination with Globalink Investment Inc, a Delaware-incorporated special purpose acquisition company. The transaction documentation referenced an amended and restated merger agreement and a two-step merger process, including a redomestication merger and an acquisition merger, after which Alps Life Sciences Inc became a wholly owned subsidiary of ALPS Group Inc.
The company has also disclosed a private investment in public equity (PIPE) subscription with certain investors in connection with the business combination, intended to support its growth strategy and working capital needs. These details underscore that ALPS Group Inc emerged as a publicly traded biotechnology and healthcare platform through a SPAC business combination route.
Geographic and listing context
In its public announcements, ALPS Group Inc notes that its headquarters will be located in Kuala Lumpur, Malaysia following the closing of the business combination. The company’s ordinary shares are stated to trade on the Nasdaq Stock Market under the symbol ALPS, while its warrants are described as trading on the over-the-counter market under a separate symbol. The company also frames its ambitions in terms of contributing to biotechnology development and healthcare accessibility on a global scale.
Stated mission and healthcare orientation
ALPS Group Inc’s mission statements emphasize creating what it calls a fair healthcare ecosystem. This involves advancing predictive, preventive, and precision medicine and focusing on making advanced therapies more accessible and affordable. The company’s communications reference genomics, mRNA and personalized vaccines, and cellular therapies in the context of its broader mission to improve healthcare outcomes, though detailed product-level descriptions are not provided in the available materials.
Within this framework, ALPS Group Inc presents itself as uniting science, technology, and healthcare practice in a single platform, with an emphasis on advanced therapies and personalized approaches to medicine. The company also references initiatives intended to support a biotechnology ecosystem, such as the development of a biotechnology hub concept, as part of its broader narrative about contributing to healthcare innovation and collaboration.
Management and governance developments
In its public disclosures, ALPS Group Inc has highlighted changes in its leadership team. The company announced the appointment of a Chief Financial Officer responsible for financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury functions for ALPS Group and its subsidiaries. The company also notes that, upon completion of the business combination, the executive officers of Alps Life Sciences Inc immediately prior to closing became the initial executive officers of ALPS Group Inc, with its chief executive officer also serving as chairman of the board of directors.
These disclosures indicate a focus on establishing a governance and financial framework to support the company’s stated growth plans and its role as a publicly traded biotechnology and healthcare platform.
Relationship to former ALPS-ticker energy company
The ticker symbol ALPS was previously associated in news reports with Alpine Summit Energy Partners, Inc., a U.S.-based company that operated and developed oil and gas assets. That company announced a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas and described itself as operating and developing oil and gas assets. Those historical disclosures relate to a different business profile and corporate entity than ALPS Group Inc’s current description as an integrated biotechnology research and healthcare platform. Users researching the symbol ALPS may therefore encounter both the historical energy company context and the more recent biotechnology and healthcare platform associated with ALPS Group Inc.
Investor considerations
Public information about ALPS Group Inc emphasizes its identity as a biotechnology and healthcare platform, its Nasdaq listing under the symbol ALPS, its headquarters location in Kuala Lumpur, Malaysia, and its role as the parent of Alps Life Sciences Inc. Investors and observers examining this company may wish to review its public filings and press releases for more detailed information about its operations, risk factors, and corporate structure, while also recognizing the historical use of the ALPS ticker by Alpine Summit Energy Partners, Inc. in the oil and gas sector.
Frequently Asked Questions
Alps Group Inc. investment returns
How much would $1,000 invested in Alps Group Inc. be worth today?
If you invested $1,000 in Alps Group Inc. (ALPS) 1 years ago on 2025-10-31, your investment would be worth $125 as of 2026-08-14, representing a -87.5% total return, growing at a compounded rate of -92.9% per year (CAGR).
Has Alps Group Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare ALPS performance over available time periods.
What is Alps Group Inc.'s average annual return?
The compound annual growth rate (CAGR) of ALPS over the past 1 years is -92.9%, growing at a compounded rate each year. Individual years vary significantly — ALPS's best recent year was 2022 (+46.6%) and worst was 2023 (-99.7%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
